At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Trametinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
In Brief
A Phase 2 clinical trial evaluating Questionnaire Administration and Trametinib for Locally Advanced Epithelioid Hemangioendothelioma and 2 related conditions. Completed, enrolled 44 participants across 36 sites.
Detailed Summary
This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body (metastatic), nearby tissue or lymph nodes (locally advanced), or cannot be removed by surgery (unresectable). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Epithelioid Hemangioendothelioma, Metastatic Epithelioid Hemangioendothelioma, Unresectable Epithelioid Hemangioendothelioma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJun 2017
Primary CompletionJun 2023
TodayJul 2026
First PostedMay 10, 2017
Enrollment StartJun 20, 2017
Primary CompletionJun 23, 2023
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 9.1 years ago
Interventions
Questionnaire Administrationother
Ancillary studies
Trametinibdrug
Given PO